Amgen to bring five new biologic drugs to Brazil

Biotecnology drug company Amgen has ambitious plans for the Brazilian pharmaceutical market in the short term. In the next 18 months, the US firm aims to bring to the country five new biologic drugs, which are considered the new frontier in the global industry. In addition, it plans to take part in the so-called Partnerships for Productive Development (PDP), signed between state and private-sector laboratories in order to transfer technology and ensure self-sufficiency of the domestic market for this type of medicine. In an interview with Valor, Amgen president in Brazil Mauro Loch said the drugmaker was awaiting the new list of strategic medication for the Unified Health System (SUS) to define its participation in the next PDPs.

• Tweetar